ArticlePharmacoEconomics - open2025

Cost Effectiveness of Sequencing Vedolizumab as First-Line Biologic in Ulcerative Colitis and Crohn's Disease in Canada: An Analysis Using Real-World Evidence from the EVOLVE Study.

Aren Fischer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.